Quick Answer
Insight Molecular Diagnostics Inc. reported Operating Income Loss of -$51.12 million for the year ending 2025.
- Insight Molecular Diagnostics Inc. showed an increase of +16.2% in Operating Income Loss from 2024 to 2025.
- This data is from Insight Molecular Diagnostics Inc.'s annual report (Form 10-K), filed with the SEC on March 26, 2026.
- XBRL data for this metric is available from 2014 to 2025 (12 years of filings). Earlier data may not exist in machine-readable XBRL format as companies adopted electronic filing at different times.
- Over the full 12 years of available data (2014 to 2025), Insight Molecular Diagnostics Inc.'s Operating Income Loss has declined by 928.0%.
- Historical annual values: Fiscal year 2025: -$51.12 million | Fiscal year 2024: -$61.04 million | Fiscal year 2023: -$25.14 million | Fiscal year 2022: -$18.00 million | Fiscal year 2021: -$53.73 million | Fiscal year 2020: -$29.71 million | Fiscal year 2019: -$22.24 million | Fiscal year 2018: -$15.20 million | Fiscal year 2017: -$18.85 million | Fiscal year 2016: -$11.14 million | Fiscal year 2015: -$8.72 million | Fiscal year 2014: -$4.97 million.
- Data sourced from SEC EDGAR public filings as of June 21, 2026.
Last verified: